Trial Profile
A Randomized, Controlled Phase II Clinical Trial of Apatinib in Combination With EGFR-TKI Versus EGFR-TKI for Non-squamous, Non-small Cell Lung Cancer(NSCLC) With T790M-negative After the Failure of EGFR-TKI Therapy
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Sep 2022
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Erlotinib; Gefitinib; Imatinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 05 Jan 2018 New trial record